Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 398 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
398 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Open-label dose-escalation study of oral KST-6051, an investigational pan-KRAS inhibitor targeting both active and inactive KRAS conformations, in adults with locally advanced unresectable or metastatic KRAS-mutant solid tumors including NSCLC, pancreatic, colorectal, and other cancers. Patients must have progressed after or been intolerant of standard therapy, have ECOG 0-1 and measurable disease, with no prior/current RAS/KRAS inhibitor therapy or CNS metastases.
ClinicalTrials.gov ID: NCT07458347
TrialFetch AI summary: Adults with stage III/IV NSCLC and ECOG 0–1 after prior advanced-setting therapy including anti–PD-1/PD-L1, with secondary/acquired ICI resistance; later cohorts require prior platinum chemotherapy and docetaxel as third-line population. Treatment is IV THIO, an investigational telomere-targeting 6-thio-dG that induces telomere dysfunction/DNA damage in telomerase-positive tumor cells, given alone or sequenced before cemiplimab anti–PD-1.
ClinicalTrials.gov ID: NCT05208944
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral TRI-611, a brain-penetrant ALK molecular glue degrader that promotes cereblon-mediated degradation of ALK fusion proteins, in adults with advanced measurable ALK-positive NSCLC. Cohorts include heavily ALK TKI–pretreated patients, including post-lorlatinib and post-neladalkib settings, as well as an ALK TKI–naïve cohort; stable CNS metastases are allowed.
ClinicalTrials.gov ID: NCT07491497
TrialFetch AI summary: Adults with advanced/metastatic PTK7-expressing solid tumors, including non-squamous EGFR-wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial carcinoma, receive HWK-007 IV every 3 weeks. HWK-007 is an investigational PTK7-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose escalation/expansion focused on safety, dose selection, pharmacokinetics, immunogenicity, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07444814
TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced c-Met–expressing solid tumors after standard therapy, with expansion cohorts emphasizing MET-amplified and/or c-Met–overexpressing nonsquamous NSCLC after prior platinum, immunotherapy, and targeted therapy when applicable. All patients receive CKD-703, a c-Met–targeted antibody–drug conjugate delivering the microtubule toxin MMAE.
ClinicalTrials.gov ID: NCT07439094
TrialFetch AI summary: Patients with ECOG 0–2 and measurable, unresectable locally advanced or metastatic solid tumors, including colorectal cancer, NSCLC, breast cancer, and upper GI adenocarcinomas; expansion focuses on refractory colorectal cancer and NSCLC. All receive IV IM-1617, an antibody–drug conjugate targeting an undisclosed receptor tyrosine kinase and delivering the HC74 topoisomerase-I inhibitor payload.
ClinicalTrials.gov ID: NCT07578571
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that have progressed on, or are unsuitable or intolerant of, standard therapy receive once-daily oral SHY-ONC6. SHY-ONC6 is a small-molecule proteasome inhibitor targeting selected AAA+ ATPases in the 19S regulatory particle to disrupt ubiquitinated protein processing and promote apoptosis.
ClinicalTrials.gov ID: NCT07705334
TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.
ClinicalTrials.gov ID: NCT07339176
TrialFetch AI summary: Adults with previously treated metastatic pancreatic ductal adenocarcinoma, NSCLC, or colorectal cancer harboring KRAS G12C/D/V/A/S or G13D mutations, measurable disease, and ECOG 0–1 are eligible. Participants receive oral once-daily BLU-924 (SAR449336), an investigational pan-KRAS small-molecule inhibitor, as monotherapy.
ClinicalTrials.gov ID: NCT07629960
TrialFetch AI summary: Adults with HLA-A*11:01-positive, KRAS G12V-mutant metastatic pancreatic, biliary, colorectal, or non-small cell lung cancer after standard therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous TCR-engineered T cells recognizing HLA-A*11:01-presented KRAS G12V and targeting ILT4/LILRB2-positive immunosuppressive cells; prophylactic tocilizumab is given on day 2.
ClinicalTrials.gov ID: NCT07594067